A knee consultation should give you clear choices

The exam comes before the treatment talk

The examiner needs to hear how the knee affects your day. Explain whether it aches after rest, on stairs, or during the night. Mention a fall, locking, or sudden swelling. Those facts can change which kind of care makes sense.

Ask why the joint seems sore and whether therapy, medicine, or another doctor belongs first. A sound answer includes the limits of each choice. It shouldn’t make one visit sound like a sure fix.

Ask for the full regenerative medicine cost before deciding. Get the total price in writing, including every planned visit. Insurance may not cover biologic therapies, meaning clinic procedures prepared from your blood or bone marrow. Don’t let pressure that day rush a choice involving your savings.

If soreness remains, QC Kinetix can explain its non-surgical options

If soreness remains, QC Kinetix can explain its regenerative treatments. The clinic draws blood or bone marrow, prepares a chosen portion, and places that portion into the knee. The clinic’s medical providers examine your knee and carry out the procedure. They’ll decide whether these non-surgical choices may fit.

When PRP is proposed, the letters mean platelet-rich plasma. The clinic spins a blood sample so platelets gather in one part. Concentrated PRP has a higher share of those tiny blood parts. The clinic may call these natural pain treatments because the starting blood or marrow comes from your body.

Ask what will be drawn, how it will be prepared, and what the next days may bring. Find out which changes mean you need to contact the clinic. Compare the price, limits, and recovery with knee replacement alternatives. Your health, needs, and budget all belong in that decision.

Sources

1. A dual systematic review compared the RCT evidence on injectable orthobiologics for knee OA with how news media describe it. Of 14 qualifying RCTs, 8 showed significant pain improvement and 10 function improvement, with frequent heterogeneity and risk of bias. Of 124 news articles: 79.0% highlighted benefits, only 29.8% mentioned drawbacks, 37.1% used the term 'stem cell' without specifying the product, 35.5% mentioned commercial entities with no disclosure, and 66.1% were favourable in tone. The authors conclude this disconnect encourages unrealistic expectations.

   Zhang EJX, et al. — Disparities in Evidence and Media Portrayal of Injectable Orthobiologics for Knee Osteoarthritis: A Systematic Review of Randomized Trials and News Media.. Orthopaedic journal of sports medicine, 2026. DOI: 10.1177/23259671261443876.

2. FDA's public list of licensed cellular and gene therapy products is the checkable answer to 'is this FDA-approved?'. A product not on that list, and not being administered under an active IND, is not an approved therapy however it is described in a brochure. For orthopedics the list is short and its cartilage entry is MACI, indicated for focal full-thickness knee defects.

   US Food and Drug Administration, Center for Biologics Evaluation and Research — Approved Cellular and Gene Therapy Products. FDA, 2026.

3. FDA states plainly that no stem cell, exosome, stromal vascular fraction, umbilical cord blood, Wharton's jelly or amniotic-fluid product has been approved for the treatment of ANY orthopedic condition - it names osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain and shoulder pain individually. The only FDA-approved stem cell products in the United States are cord-blood-derived blood-forming stem cells for disorders of the hematopoietic system, and there are currently no FDA-approved exosome products.

   US Food and Drug Administration, Center for Biologics Evaluation and Research — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. FDA, 2020.

4. A cross-sectional study contacted 273 of 317 US centres offering direct-to-consumer stem-cell therapy, posing as a 57-year-old man with knee osteoarthritis. The mean advertised price of a unilateral same-day stem-cell knee injection was $5,156 (SD $2,446), and centres claimed a mean clinical efficacy of 82% (SD 9.6%) - a figure with no support in the published evidence. The gap between the quoted number and the trial data is the single most useful thing a patient can be told before a consultation.

   Piuzzi NS, et al. — The Stem-Cell Market for the Treatment of Knee Osteoarthritis: A Patient Perspective.. The journal of knee surgery, 2018. DOI: 10.1055/s-0037-1604443.

5. In January 2025 the Federal Trade Commission banned the co-founders of a stem cell institute and their companies from marketing stem cell treatments and ordered them to pay more than $5.1 million in refunds and civil penalties. Deceptive EFFICACY ADVERTISING, not merely unapproved manufacturing, is independently actionable - the FTC polices what a clinic promises as well as what it injects.

   US Federal Trade Commission — Stem Cell Institute Co-Founders and Companies Banned from Marketing Stem Cell Treatments and Ordered to Pay More Than $5.1 Million for Refunds and Civil Penalties. FTC Press Release, 2025.